利妥昔单抗联合CHOP方案对弥漫型大B细胞淋巴瘤的疗效及影响因素

目的探讨利妥昔单抗联合CHOP方案对弥漫型大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL)的疗效,观察影响化疗疗效的相关因素。方法本组选择我院2006年1月至2011年1月收入的DLBCL患者17例,患者给予利妥昔单抗联合CHOP方案治疗。观察化疗后疗效及淋巴结亚群改变情况,收集患者的性别、年龄、PS评分、Ann Arbor分期、结外浸润情况、LDH水平、体力状态(PS)评分、B症状、血红蛋白及T细胞浸润等相关情况,观察其对化疗的相关影响。结果本组所有17例患者完成治疗,治疗后疗效评估显示CR7例,PR6例,SD3例,PD1例,治疗有效率为76.4%(13/17)。影响化疗疗效相关因素分析中显示,血清LDH水平、PS评分、AnnArbor分期为影响患者化疗疗效的相关因素,P0.05。结论利妥昔单抗联合CHOP对弥漫型大B细胞淋巴瘤疗效显著,其中PS评分低、Ann Arbor分期低、血清LDH水平正常的患者化疗疗效相对较好。

The therapeutic efficacy of rituximab in combination with CHOP on diffuse large B-cell lymphoma and influencing factors

Objective To investigate the therapeutic efficacy of rituximab in combination with CHOP on diffuse large B-cell lymphoma(DLBCL) and observe the factors related to the therapeutic efficacy for chemotherapy.Methods 17 DLBCL patients hospitalized in our hospital from January 2006 to January 2011 were included in the present study,and they were subjected to the treatments with rituximab in combination with CHOP.Therapeutic efficacy and changes in lymph node subsets were observed after chemotherapy,name,age,PS score,Ann Arbor staging,extracapsular infiltration,LDH level and physical status(PS) score,B symptom,hemoglobin and T lymphocyte infiltration and other parameters were collected from these patients,and the effects of these parameters on chemotherapy were observed.Results All of the 17 patients accomplished the treatments in the present study,the therapeutic efficacy assessment results were as followed:7 cases of complete remission,6 cases of partial remission,3 cases of stable disease,and 1 case of progression of disease,and the effective rate for the treatments was 76.4%(13/17).It was found in the analysis on the factors influencing the therapeutic efficacy of chemotherapy that serum LDH level,PS score and Ann Arbor staging were factors influencing the therapeutic efficacy of chemotherapy for the patients,P<0.05.Conclusion The therapeutic efficacy for the treatments on diffuse large B-cell lymphoma(DLBCL) by using rituximab in combination with CHOP is significant,and the therapeutic efficacy is relatively satisfactory in the patients with low PS score,low Ann Arbor staging and normal serum LDH level.